Bruce Mitlak
Overview
Explore the profile of Bruce Mitlak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
446
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Latimer J, Yilmaz B, Feher B, Shiba T, Fretwurst T, Mitlak B, et al.
Clin Oral Implants Res
. 2025 Jan;
PMID: 39789749
Objective: Abaloparatide (ABL) is a synthetic parathyroid hormone-related protein analog developed as an anabolic drug to treat osteoporosis. ABL increases bone mineral density (BMD) of the long bones and spine;...
2.
Latimer J, Maekawa S, Shiba T, Fretwurst T, Chen M, Larsson L, et al.
JBMR Plus
. 2024 Sep;
8(10):ziae113.
PMID: 39347482
At present, a lack of consensus exists regarding the clinical impact of osteoporosis on alveolar bone metabolism during implant osseointegration. While limited preclinical and clinical evidence demonstrates a negative influence...
3.
Dhaliwal R, Kendler D, Saag K, Ing S, Singer A, Adler R, et al.
JBMR Plus
. 2024 Mar;
8(2):ziae009.
PMID: 38505522
Osteoporosis in men is an underappreciated public health issue, accounting for approximately 30% of the societal burden of osteoporosis. Although the prevalence of osteoporosis in men is lower, fracture-related morbidity...
4.
Davenport C, Gravel P, Wang Y, Williams S, Wieland A, Mitlak B
Ther Innov Regul Sci
. 2024 Feb;
58(3):505-518.
PMID: 38341388
Real-World Evidence (RWE), which has historically been used to support post-approval safety studies, has recently gained acceptance for new drug applications as supportive evidence or as new clinical evidence for...
5.
Lewiecki E, Czerwinski E, Recknor C, Strzelecka A, Valenzuela G, Lawrence M, et al.
J Bone Miner Res
. 2023 Jul;
38(10):1404-1414.
PMID: 37417725
Anabolic therapies, recommended for patients at very high fracture risk, are administered subcutaneously (SC). The objective of this study was to evaluate the efficacy and safety of the abaloparatide microstructured...
6.
Cosman F, Hans D, Shevroja E, Wang Y, Mitlak B
J Bone Miner Res
. 2023 Jan;
38(4):464-470.
PMID: 36588166
Although bone mineral density (BMD) is a predictor of fracture, many fractures occur in women with T-scores > -2.5. Bone microarchitecture, assessed by trabecular bone score (TBS), predicts fracture risk...
7.
Sato T, Castro Andrade C, Yoon S, Zhao Y, Greenlee W, Weber P, et al.
Proc Natl Acad Sci U S A
. 2022 Dec;
119(50):e2214396119.
PMID: 36472957
Osteoporosis is a major public health problem. Currently, there are no orally available therapies that increase bone formation. Intermittent parathyroid hormone (PTH) stimulates bone formation through a signal transduction pathway...
8.
Czerwinski E, Cardona J, Plebanski R, Recknor C, Vokes T, Saag K, et al.
J Bone Miner Res
. 2022 Oct;
37(12):2435-2442.
PMID: 36190391
Abaloparatide significantly increased bone mineral density (BMD) in women with postmenopausal osteoporosis and decreased risk of vertebral, nonvertebral, and clinical fractures compared with placebo. The Abaloparatide for the Treatment of...
9.
Eastell R, Vittinghoff E, Lui L, McCulloch C, Pavo I, Chines A, et al.
J Bone Miner Res
. 2021 Sep;
37(1):29-35.
PMID: 34490915
The surrogate threshold effect (STE) is defined as the minimum treatment effect on a surrogate that is reliably predictive of a treatment effect on the clinical outcome. It provides a...
10.
Miller P, Troy S, Weiss R, Annett M, Schense J, Williams S, et al.
Clin Drug Investig
. 2021 Feb;
41(3):277-285.
PMID: 33638863
Background And Objective: Abaloparatide, an anabolic osteoporosis treatment administered by subcutaneous (SC) injection, increases bone mineral density (BMD) and reduces fracture risk in postmenopausal women with osteoporosis. The abaloparatide-solid Microstructured...